논문실적
Home › 연구실적 › 논문실적
- 365Application of the Hollow-Fiber Infection Model to Personalized Precision Dosing of Isoniazid in a Clinical Setting
Park YM, Tung PM, Anh NK, Cho YS, Shin JG · J Korean Med Sci. 8;39(13):e104 / 2024.04 · 2024 cPMTb
- 364Emerging and upcoming therapies in insomnia
Kim WJ, Kim HS · Transl Clin Pharmacol. 32(1):1-17 / 2024.03 · 2024 IPPM
- 363Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure
Hoa PQ, Kim HK, Jang TW, Seo HW, Oh JY, Kim HC, Shin AY, Min JS, Jayanti RP, Hung TM, Anh NK, Ahn SZ, Long NP, Cho YS, Shin JG, cPMTb · Int J Antimicrob Agents. 63(2):107034 / 2024.02 · 2024 cPMTb
- 362Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia
Moon JJ, Kim HS, Shim JC, Ahn JM, Jung DU, Kim DJ, Jeong HE, Kim EY, Jeon DW, Kim SJ, Shin JG · Int Clin Psychopharmacol. 1;39(1):29-35 / 2024.01 · 2024 cPMTb
- 361Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database
Seo WJ, Koo HK, Kang JY, Kang JE, Park SH, Kang HK, Park HK, Lee SS, Choi SB, Jang TW, Shin KC, Oh JY, Choi JY, Min JS, Choi YK, Shin JG, Cho YS · BMC Pulm Med. 24;23(1):471 / 2023.11 · 2023 cPMTb
- 360Exploring the Influence of VDR Genetic Variants TaqI, ApaI, and FokI on COVID-19 Severity and Long-COVID-19 Symptoms
Alhammadin G, Jarrar Y, Madani A, Lee SJ · J Pers Med. 28;13(12):1663 / 2023.11 · 2023 cPMTb
- 359Unveiling potentially convergent key events related to adverse outcome pathways induced by silver nanoparticles via cross-species omics-scale analysis
Anh NH, Min YJ, Nhung TTM, Long NP, Han SH, Kim SJ, Jung CW, Yoon CY, Kang YP, Park SK, Kwon SW · J Hazard Mater. 5:459:132208 / 2023.10 · 2023 cPMTb
- 358Molecular and Metabolic Phenotyping of Hepatocellular Carcinoma for Biomarker Discovery: A Meta-Analysis
Anh NH, Long NP, Min YJ, Ki YJ, Kim SJ, Jung CW, Park SO, Kwon SW, Lee SJ · Metabolites. 27;13(11):1112 / 2023.10 · 2023 cPMTb
- 357Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers
Phat NK, Tien NTM, Anh NK, Yen NTH, Lee YA, Trinh HKT, Le KM, Ahn SZ, Cho YS, Park SO, Kim DH, Long NP, Shin JG · Front Immunol. 31:14:1210372 / 2023.10 · 2023 cPMTb
- 356A use case of ChatGPT in a flipped medical terminology course
Ahn SZ · Korean J Med Educ. 35(3):303-307 / 2023.09 · 2023 cPMTb
- 355Clinical Significance of NAT2 Genetic Variations in Type II Diabetes Mellitus and Lipid Regulation
Jarrar Y, Abudahab S, Abdul-Wahab G, Zaiter D, Madani A, Abaalkhail SJ, Abulebdah D, Alhawari H, Musleh R, Lee SJ · Pharmgenomics Pers Med. 13:16:847-857 / 2023.09 · 2023 cPMTb
- 354Bioactive-Guided Phytochemical Investigations, In Vitro and In Silico Alpha-Glucosidase Inhibition of Two Vietnamese Medicinal Plants Dicranopteris linearis and Psychotria adenophylla
Duong TH, Vu YT, Long NP, Phan NHN, Pham NKT, Sichaem J, Kieu NKD, Duong CB, Nguyen TT, Dang VS, Nguyen HT · Pharmaceuticals(Basel). 5;16(9):1253 / 2023.09 · 2023 cPMTb
- 353Transforming clinical trials: the emerging roles of large language models
Ghim JL, Ahn SZ · Transl Clin Pharmacol. 31(3):131-138 / 2023.09 · 2023 cPMTb
- 352Genome-wide kinase-MAM interactome screening reveals the role of CK2A1 in MAM Ca2+ dynamics linked to DEE66
Nhung TTM, Long NP, Nghi TD, Suh YJ, Anh NH, Jung CW, Triet HM, Jung MK, Woo YS, Yoo JY, Noh SJ, Kim SJ, Lee SB, Park SO, Thomas G, Simmen T, Mun JY, Rhee RW, Kwon SW, Park SK · Proc Natl Acad Sci U S A. 8;120(32):e2303402120 / 2023.08 · 2023 cPMTb
- 351Pathway-level multi-omics analysis of the molecular mechanisms underlying the toxicity of long-term tacrolimus exposure
Yen NTH, Phat NK, Oh JH, Park SM, Moon KS, Thu VTA, Cho YS, Shin JG, Long NP, Kim DH · Toxicol Appl Pharmacol. 15:473:116597 / 2023.08 · 2023 cPMTb